Penicillin V
Phase 3Small molecule
Penicillin V is one of 53 small molecule programs targeting Pneumonia. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Penicillin V
CCorewell Health East
Phase 3
Jakafi
IncytePreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Pepcid
KKenvue Brands
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Tylenol
KKenvue Brands
Preclinical
Prograf
VVeloxis Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pneumonia1 trial
Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.
Terminated·FFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina·Phase 3·NCT03208361·43 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Penicillin V. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCorewell Health East